BioSpace News Archive

Riverain Technologies™, a leader in artificial intelligence (AI) for early, efficient detection of lung nodules, will showcase its solutions and enhancements at the 107th Annual Radiological Society of North America (RSNA) meeting.

Marathon Asset Management Announces Acquisition of Kaléo.

Artelo Biosciences, Inc., a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, reported financial and operating results for the fiscal year ended August 31, 2021 and provided a business update.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the REDEEM-2 pivotal trial with its oral Factor D inhibitor, BCX9930, in patients with paroxysmal nocturnal hemoglobinuria (PNH).

Emmes today announced that it conducted the data and statistical analysis for the third iteration of the Adaptive COVID-19 Treatment Trial (ACTT-3), using its proprietary Advantage eClinical system.

Gilead Sciences, Inc. (Nasdaq: GILD) will present additional data from the Phase 3 ASCENT study of Trodelvy® (sacituzumab govitecan-hziy) during the upcoming San Antonio Breast Cancer Symposium (SABCS) being held from December 7-10.

Nabriva Therapeutics plc (NASDAQ: NBRV), announced today that its partner, Sumitomo Pharmaceuticals’ (Suzhou) Co., Ltd., new drug application (NDA) to market oral and intravenous (IV) formulations of lefamulin for the treatment of community-acquired pneumonia (CAP) in adults in mainland China has been accepted for review by the Chinese Center for Drug Evaluation (CDE), China’s regulatory authority, on November 23, 2021.

OriCiro Genomics Inc., a pioneer in cell-free synthesis and amplification of genome-scale large DNA for advanced therapeutics and synthetic biology, today announced the launch of OriCiro® Cell-Free Switching system.

Kaiser Permanente research in Southern California published Nov. 25, 2021, in The Lancet Regional Health – Americas confirmed high Moderna COVID-19 vaccine effectiveness up to 5 months after the second dose.

Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, today announced it has completed an analysis of the SARS-CoV-2 B.1.1.529 variant, designated by the World Health Organization as Omicron.